

August 2021 Newsletter



August 2021 iConquerMS Spotlight

Power COVID-19 Vaccine Research With Your Data!


On August 23, 2021, the U.S. Food and Drug Administration (FDA) approved the Pfizer-BioNTech vaccine for the prevention of COVID-19 disease in individuals 16 years of age and older. The vaccine, which will now be marketed as Comirnaty, continues to be available under emergency use authorization for individuals 12 to 15 years of age and for the



administration of a third dose in people who are not expected to have a normal or adequate immune responses after two doses of the vaccine, such as people with MS on [certain disease modifying therapies](#).

The National MS Society recently updated its [COVID-19 vaccine guidance](#) as follows, “People with MS age 12* and older who are fully vaccinated with an mRNA vaccine may be eligible to receive an additional vaccine dose now. Talk with your healthcare provider to determine the best time to get your additional dose.” (* Only the Pfizer/BioNTech

vaccine is authorized for age 12 and older.) The Society’s guidance is based on available data from studies (which are ongoing) and the opinions of [MS experts](#).



The [COVER-MS study](#) (COVID-19 VaccinE Response in MS) is underway to collect data from iConquerMS members about their experience with the COVID-19 vaccines. All adults affected by MS are eligible (21 or older) and welcome to participate.

Participants will be asked to complete a few short surveys on the iConquerMS portal at different timepoints. These surveys contain questions about demographics, MS characteristics, COVID-19 infection, COVID-19 vaccines received, reactions to them, and any MS symptoms experienced before and after vaccination. The data collected will provide a better understanding of the short- and longer-term effects of the vaccines in the MS population. A third round of surveys will soon be released for those fully vaccinated individuals that elect to receive a booster shot. Stay tuned!

Real-world data from COVER-MS will complement the available guidance and provide additional assurance for those with MS who are planning to get vaccinated. If you are an iConquerMS member that has received a COVID-19 vaccine, please [login](#) today and share your experience by clicking on “Participate in the COVID-19 Vaccination Study.”

Forgotten to report your experience with your second shot? It’s not too late! If you’re not yet a member of iConquerMS, please [join](#) the network and start powering MS research with your data today!

